Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The American Journal of Pathology|July 5, 2008
CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor developmentEverardo Macias, Paula L Miliani de Marval, Adriana De Siervi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1)Vyomesh Patel, Tyler Lahusen, Chidchanok Leethanakul, et al.
The Journal of Biological Chemistry|May 15, 2003
Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformationDavid A Solomon, Ying Wang, Sejal R Fox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasmsAntoinette R Tan, Donna Headlee, Richard Messmann, et al.
Anti-Cancer Drugs|February 6, 2003
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasmsSuoping Zhai, Edward A Sausville, Adrian M Senderowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6Richard A Messmann, Claudio Dansky Ullmann, Tyler Lahusen, et al.
Molecular Carcinogenesis|October 23, 2008
Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b)Paola Rojas, Fernando Benavides, Jorge Blando, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporineAlex Sparreboom, Huachen Chen, Milin R Acharya, et al.
The Annals of Pharmacotherapy|October 2, 2003
Clinical pharmacology of flavopiridol following a 72-hour continuous infusionMichelle A Rudek, Kenneth S Bauer, Richard M Lush, et al.
Cancer Research Communications|March 16, 2023
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory LymphomaKristie A Blum, Jeffrey G Supko, Michael B Maris, et al.
Pageof 4